# Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

> **NCT06532565** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 154 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** GS-2121
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT06532565
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-26
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532565, "Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06532565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*